Insights from 2023 ESMO World Congress on Gastrointestinal Cancer Annual Meeting
2023 ESMO WCGIC Insights: "Additional Results From the Phase 3 NAPOLI 3 Trial - NALIRIFOX vs. nab-Paclitaxel + Gemcitabine in Treatment-Naïve Patients With mPDAC"
Comments 0
Login to view comments.
Click here to Login
